Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

LANNETT COMPANY, INC. (LCI)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2018 688 M
EBIT 2018 226 M
Net income 2018 84,7 M
Debt 2018 725 M
Yield 2018 -
Sales 2019 678 M
EBIT 2019 201 M
Net income 2019 90,5 M
Debt 2019 665 M
Yield 2019 -
P/E ratio 2018 10,25
P/E ratio 2019 8,73
EV / Sales2018 1,99x
EV / Sales2019 1,93x
Capitalization 645 M
More Financials
Company
Lannett Co., Inc. engages in the development, manufacture, market, and distribution of generic pharmaceutical products.The firm also manufactures oral dosage forms including, tablets and capsules.Its pharmaceutical products are distributed to drug wholesalers, chain drug retailers, private label... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of Lannett Company, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on LANNETT COMPANY, INC.
02/09LANNETT : Announces Fiscal 2018 Second-Quarter Financial Results Reports Record ..
AQ
02/08LANNETT : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
02/08LANNETT CO INC : Results of Operations and Financial Condition (form 8-K)
AQ
02/08LANNETT : beats 2Q profit forecasts
AQ
02/07LANNETT : Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record..
PR
02/07LANNETT : Voluntarily Pays Down $25 Million Of Term Loans
PR
02/05LANNETT : Enters Into Consulting Agreement with Former CEO, Arthur Bedrosian
AQ
02/02LANNETT : To Report Fiscal 2018 Second-Quarter Financial Results, Host Conferenc..
AQ
02/01LANNETT : Enters Into Consulting Agreement With Former CEO, Arthur Bedrosian
PR
01/31LANNETT : To Report Fiscal 2018 Second-Quarter Financial Results, Host Conferenc..
PR
More news
Sector news : Pharmaceuticals - NEC
12:41pMERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 7
Average target price 25,0 $
Spread / Average Target 47%
EPS Revisions
Managers
NameTitle
Timothy C. Crew Chief Executive Officer & Director
Jeffrey Farber Chairman
John Kozlowski Chief Operating Officer, VP-Financial Operations
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Sector and Competitors
1st jan.Capitalization (M$)
LANNETT COMPANY, INC.645
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359